<DOC>
	<DOCNO>NCT02300025</DOCNO>
	<brief_summary>This study open-label , multi-center , single-dose , parallel group study determine pharmacokinetics , safety , tolerability cobimetinib administer 10 mg fast male female adult subject vary degree hepatic function . The study conduct base Child-Pugh classification hepatic impairment . The anticipated duration study 7.5 week . The target sample size : 18 volunteer vary degree hepatic function 12 healthy control volunteer .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Safety Cobimetinib Volunteers With Without Liver Damage</brief_title>
	<detailed_description />
	<criteria>Male female subject 18 74 year age , inclusive Body weight &gt; /=45 kg body mass index 17 41 kg/m2 , inclusive Subjects hepatic impairment must ChildPugh score 5 6 ( mild ) , 7 9 ( moderate ) , 10 15 ( severe ) stable hepatic insufficiency within 1 month prior Screening stable medication regimen least 1 month prior Checkin Agreement use highly effective contraceptive method define protocol Significant illness , include infection , hospitalization within 2 week prior dose , except subject hepatic impairment due liver disease may affect significant medical problem require frequent hospitalization . Invasive systemic fungal infection need fully treat prior study entry Significant history clinical manifestation cardiac event would put subject risk opinion Investigator Use drug abuse within 1 month Screening entire study Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>